Is it possible to estimate the parameters of the sigmoid Emax model with truncated data typical of clinical studies?

Many drug concentration-effect relationships are described by the nonlinear sigmoid E(max) model. Clinical considerations frequently limit the magnitude of effect intensity that may be produced; the most pronounced effect intensity may be considerably below E(max). We have tested and quantified the influence of this limitation on the estimatability of the sigmoid E(max) model parameters. We have used the estimated parameter values to calculate data descriptors (drug concentrations required to produce certain effect intensities) and compared these with concentrations determined by using exact parameter values. We found that when the highest measured effect intensity was less than 95% of E(max), E(max) and EC50 were poorly estimated (high coefficient of variation and pronounced bias). Nevertheless, the fit to the data was quite good and the data descriptors were estimated with precision within the range for which data were available but not beyond. Baseline effect was estimated with good precision but the sigmoidicity parameter (gamma) was highly variable. Thus, where clinical considerations prevent determination of concentration-effect data near the maximum effect intensity, E(max) and EC50 estimations are unreliable. The use of estimable data descriptors is proposed to characterize the concentration-effect relationship under these conditions.

[1]  Margaret Wood,et al.  Ethnic differences in response to morphine , 1993 .

[2]  D. G. Watts An Introduction to Nonlinear Least Squares , 1981 .

[3]  H J Motulsky,et al.  Fitting curves to data using nonlinear regression: a practical and nonmathematical review , 1987, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[4]  T. Barratt,et al.  Decreased sensitivity to heparin in vitro in steroid-responsive nephrotic syndrome. , 1987, Kidney international.

[5]  J. Hunter,et al.  Effect of age, gender and anaesthetic technique on the pharmacodynamics of atracurium. , 1993, British Journal of Anaesthesia.

[6]  J. M. Hanna,et al.  Between- and within-race variation in acute cardiovascular responses to alcohol: Evidence for genetic determination in normal males in three races , 1986, Behavior genetics.

[7]  M. Hoag,et al.  HEREDITARY TRANSMISSION OF EXCEPTIONAL RESISTANCE TO COUMARIN ANTICOAGULANT DRUGS. THE FIRST REPORTED KINDRED. , 1964, The New England journal of medicine.

[8]  W. Burke,et al.  Opioid receptor density changes in Alzheimer amygdala and putamen , 1993, Brain Research.

[9]  J. Black,et al.  Operational models of pharmacological agonism , 1983, Proceedings of the Royal Society of London. Series B. Biological Sciences.

[10]  G R Wilkinson,et al.  Racial differences in drug response. Altered sensitivity to and clearance of propranolol in men of Chinese descent as compared with American whites. , 1989, The New England journal of medicine.

[11]  Stephen M. Mann,et al.  Resistance to succinylcholine in myasthenia gravis: a dose-response study. , 1988, Anesthesiology.

[12]  Identifiability and parameter estimation. , 1991, JPEN. Journal of parenteral and enteral nutrition.

[13]  L. Endrenyi,et al.  Design of experiments for the precise estimation of dose-response parameters: the Hill equation. , 1986, Journal of theoretical biology.

[14]  H. Akaike A new look at the statistical model identification , 1974 .

[15]  Paul Chay,et al.  Pharmacokinetic‐pharmacodynamic relationships of morphine in neonates , 1992, Clinical pharmacology and therapeutics.

[16]  R. Feldman,et al.  Vascular α‐adrenergic responsiveness is reduced in cirrhosis , 1994 .

[17]  A Schumitzky,et al.  A program package for simulation and parameter estimation in pharmacokinetic systems. , 1979, Computer programs in biomedicine.

[18]  D. Verotta,et al.  Aging effects on stereoselective pharmacokinetics and pharmacodynamics of verapamil. , 1993, The Journal of pharmacology and experimental therapeutics.

[19]  G Levy,et al.  Concentration‐ or effect‐controlled clinical trials with sparse data , 1994, Clinical pharmacology and therapeutics.

[20]  J. Reich On Parameter Redundancy in Curve Fitting of Kinetic Data , 1981 .

[21]  D. J. Currie Estimating Michaelis-Menten Parameters: Bias, Variance and Experimental Design , 1982 .

[22]  L. Endrenyi,et al.  Optimal design of experiments for the estimation of precise hyperbolic kinetic and binding parameters. , 1981, Journal of theoretical biology.

[23]  P. Kroboth,et al.  Alprazolam in end‐stage renal disease. II. Pharmacodynamics , 1992, Clinical pharmacology and therapeutics.